-
公开(公告)号：EP4279128A3
公开(公告)日：2024-02-28
申请号：EP23196718.3
申请日：2015-12-29
发明人： KIM, Dong-Sik , LEE, Mi Jung , PARK, Jae Chan , LEE, Sumin , KWAK, Heechun , HWANG, SungHo , LIM, Hyung-Kwon , KIM, Kisu , PARK, Young Seoub , JEONG, Junhong , CHO, Ki Joon
IPC分类号： C07K16/38 , C12N15/63 , A61K39/395 , A61P7/04 , A61P7/00
摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
-
公开(公告)号：EP4279128A2
公开(公告)日：2023-11-22
申请号：EP23196718.3
申请日：2015-12-29
发明人： KIM, Dong-Sik , LEE, Mi Jung , PARK, Jae Chan , LEE, Sumin , KWAK, Heechun , HWANG, SungHo , LIM, Hyung-Kwon , KIM, Kisu , PARK, Young Seoub , JEONG, Junhong , CHO, Ki Joon
IPC分类号： A61P7/04
摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
-
公开(公告)号：EP3954711A1
公开(公告)日：2022-02-16
申请号：EP20788397.6
申请日：2020-04-06
发明人： PARK, Jae Chan , SONG, Eun Jung , LIM, So Jung , LEE, Jae-Chul , KWON, Hae Naem , LEE, Su A , LIM, Ok Jae , KIM, Mun Kyung , CHO, Hyun Jung , KIM, Gil-Jung , LEE, Jee Won , KIM, Sung Keun , WON, Jong Wha , JANG, Shin A
摘要： The present invention relates to a bispecific anti-GPNMB/anti-CD3 antibody specifically binding to CD3 and GPNMB, and the use thereof. Particularly, the bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.
-
公开(公告)号：EP3353213B1
公开(公告)日：2020-12-02
申请号：EP16848966.4
申请日：2016-09-23
发明人： KIM, Dong-Sik , SONG, Eun Jung , LEE, Mijung , LEE, Eun-Hee , OH, Miyoung , PARK, Jae Chan , KIM, Kisu , KIM, Sujeong , LIM, Hyung-Kwon , LEE, Kyuhyun , WON, Jongwha , CHOI, Soongyu , PARK, Young Seoub
IPC分类号： C07K16/30 , C07K16/28 , A61K39/395
-
5.发明公开
公开(公告)号：EP3262075A1
公开(公告)日：2018-01-03
申请号：EP15883495.2
申请日：2015-12-29
发明人： KIM, Dong-Sik , LEE, Mi Jung , PARK, Jae Chan , LEE, Sumin , KWAK, Heechun , HWANG, SungHo , LIM, Hyung-Kwon , KIM, Kisu , PARK, Young Seoub , JEONG, Junhong , CHO, Ki Joon
IPC分类号： C07K16/36 , C12N15/63 , A61K39/395 , A61P7/04
CPC分类号： C07K16/38 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/72 , C07K2317/92
摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
-
公开(公告)号：EP3353213A1
公开(公告)日：2018-08-01
申请号：EP16848966.4
申请日：2016-09-23
发明人： KIM, Dong-Sik , SONG, Eun Jung , LEE, Mijung , LEE, Eun-Hee , OH, Miyoung , PARK, Jae Chan , KIM, Kisu , KIM, Sujeong , LIM, Hyung-Kwon , LEE, Kyuhyun , WON, Jongwha , CHOI, Soongyu , PARK, Young Seoub
IPC分类号： C07K16/30 , A61K39/395
CPC分类号： C07K16/30 , C07K16/18 , C07K2317/21 , C07K2317/565 , C07K2317/92
摘要： The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.017 秒)
